Evidence map›Paper›PMID 26038445›Full record

ReviewEmerging microbes & infections2013

Progress towards a hepatitis C virus vaccine.

Lok Man John Law, Abdolamir Landi, Wendy C Magee, D Lorne Tyrrell, Michael Houghton

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Emerging microbes & infections, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Broadening CD4Journal of virology · 2017
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Lok Man John LawLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton T6G 2E1, Canada.
Abdolamir LandiLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton T6G 2E1, Canada.
Wendy C MageeLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton T6G 2E1, Canada.
D Lorne TyrrellLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton T6G 2E1, Canada.
Michael HoughtonLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton T6G 2E1, Canada.
University of Alberta · CAInstitute of Virology of the Slovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New drugs to treat hepatitis C are expected to be approved over the next few years which promise to cure nearly all patients. However, due to issues of expected drug resistance, suboptimal activity against diverse hepatitis C virus (HCV) genotypes and especially because of their extremely high cost, it is unlikely that these HCV drugs will substantially reduce the world's HCV carrier population of around 170 million in the near future or the estimated global incidence of millions of new HCV infections. For these reasons, there is an urgent need to develop a prophylactic HCV vaccine and also to determine if therapeutic vaccines can aid in the treatment of chronically infected patients. After much early pessimism on the prospects for an effective prophylactic HCV vaccine, our recent knowledge of immune correlates of protection combined with the demonstrated immunogenicity and protective animal efficacies of various HCV vaccine candidates now allows for realistic optimism. This review summarizes the current rationale and status of clinical and experimental HCV vaccine candidates based on the elicitation of cross-neutralizing antibodies and broad cellular immune responses to this highly diverse virus.

Indexed as

HCVhepatitisinfectionprophylactictherapeuticvaccine

Identifiers

PMID26038445
PMCPMC3924556
OpenAlexW2057292812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.